Bridgebio Pharma, Inc. · NASDAQ:BBIO
KKR Genetic Disorder L.P. reported a 4.20% stake in Bridgebio Pharma, Inc. (Schedule 13D/A)
Event Aug 13, 2026 · Filed Aug 17, 2026
KKR Genetic Disorder L.P. reported a 4.20% stake in Bridgebio Pharma, Inc., 8,260,971 shares, with active intent on Aug 13, 2026. Filed Aug 17, 2026 (Schedule 13D/A).
- Stake
- 4.20%
- Shares
- 8,260,971
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 9 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| KKR Genetic Disorder L.P. | 4.20% | 8,260,971 |
| KKR Genetic Disorder GP LLC | 4.20% | 8,260,971 |
| KKR Group Partnership L.P. | 4.70% | 9,232,739 |
| KKR Group Holdings Corp. | 4.70% | 9,232,739 |
| KKR Group Co. Inc. | 4.70% | 9,232,739 |
| KKR & Co. Inc. | 4.70% | 9,232,739 |
| KKR Management LLP | 4.70% | 9,232,739 |
| Henry R. Kravis | 4.70% | 9,232,739 |
| George R. Roberts | 4.70% | 9,232,739 |
Source
Related
- Bridgebio Pharma, Inc.
- KKR Genetic Disorder L.P.
- Bridgebio Pharma, Inc. shareholders
- Schedule 13D/A · KKR Genetic Disorder L.P. · May 14, 2025
- Schedule 13D/A · KKR Genetic Disorder L.P. · Mar 7, 2025
- Form 4 · Kumar Neil · Sep 21, 2026
- Form 4 · Kumar Neil · Aug 20, 2026
- Form 4 · Kumar Neil · Aug 18, 2026
- Form 4 · Trimarchi Thomas · Aug 18, 2026
- Form 4 · Apuli Maricel · Aug 18, 2026